Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer
The Objectives of this clinical trial is to evaluate the efficacy and safety of tumor treating fields combined with gemcitabine and albumin bound paclitaxel in the treatment of locally advanced pancreatic cancer.
Locally Advanced Pancreatic Cancer
DEVICE: Tumor treating fields combined with Gemcitabine hydrochloride and albumin binding paclitaxel|DRUG: Gemcitabine hydrochloride and albumin binding paclitaxel
Overall survival (OS), From date of enrollment until the date of death from any cause, up to 12 months after the last study treatment
Number of participants with adverse events (AEs), Adverse events will be defined as the incidence, frequency and severity of adverse events (AEs) noted in patients treated with study treatments, The whole study period|Progression-free survival (PFS), Progression-free survival is defined as the time from the start of treatment with Tumor Treating Fields and Docetaxel until the first documentation of disease progression or death due to any cause, whichever occurs first, up to 30 months|12-month OS rate, 12-month Overall survival rate, 12 months|Progression Free Survival rate at 6 months, The analysis will be estimated proportions of patients who are progression-free at 6 months based on the RECIST 1.1 criteria following the time of enrollment, 6 months
The Objectives of this clinical trial is to evaluate the efficacy and safety of tumor treating fields combined with gemcitabine and albumin bound paclitaxel in the treatment of locally advanced pancreatic cancer.